Rocca Paola, Fonzo Valeria, Ravizza Luigi, Rocca Giuseppe, Scotta Monica, Zanalda Enrico, Bogetto Filippo
Department of Neuroscience, Psychiatric Section, University of Turin, via Cherasco 11, 10126 Torino, Italy.
J Affect Disord. 2002 Aug;70(3):313-7. doi: 10.1016/s0165-0327(01)00327-5.
The purpose of this study was to provide preliminary data on the effects of paroxetine and amisulpride on depressive dimensions, analyzed by factor analysis, in dysthymic patients.
One hundred and eighteen patients with DSM IV criteria for DD without concurrent major depression were enrolled in this 8-week, open study, and 100 completed it. Symptom dimensions were identified by principal components analysis with the SAS Factor procedure.
Results of the symptom rating scales indicated that both drugs were equally effective. Response rate was 65% both in the paroxetine and the amisulpride group and the proportions of patients achieving a final HRSD score < or =7 were 46.7 and 55%, respectively. MADRS factor analysis identified two factors at baseline: the first corresponding to the global severity of depression and the second to somatic symptoms. After 8 weeks of treatment only one factor could be substantiated. At week 4 both paroxetine and amisulpride produced significant improvements on factor 1 while at week 8 mean changes of factor 1 were greater in the amisulpride-treated patients.
The main limitation was the open-label design.
Both paroxetine and amisulpride appear to be effective in the short-term management of DD, improving its most characteristic symptoms.
本研究旨在提供关于帕罗西汀和阿立哌唑对恶劣心境障碍患者抑郁维度影响的初步数据,这些影响通过因子分析进行分析。
118名符合DSM-IV标准的恶劣心境障碍患者,且无并发重度抑郁症,参与了这项为期8周的开放性研究,其中100人完成了研究。症状维度通过使用SAS因子程序的主成分分析来确定。
症状评定量表的结果表明两种药物同样有效。帕罗西汀组和阿立哌唑组的有效率均为65%,最终汉密尔顿抑郁量表(HRSD)评分≤7分的患者比例分别为46.7%和55%。蒙哥马利-艾斯伯格抑郁量表(MADRS)因子分析在基线时确定了两个因子:第一个对应抑郁的总体严重程度,第二个对应躯体症状。治疗8周后仅能证实一个因子。在第4周时,帕罗西汀和阿立哌唑对因子1均产生了显著改善,而在第8周时,阿立哌唑治疗的患者中因子1的平均变化更大。
主要局限性是开放标签设计。
帕罗西汀和阿立哌唑在恶劣心境障碍的短期治疗中似乎均有效,可改善其最典型的症状。